Handelsavisen
prelaunch
Companies Healthcare DTC.CD
DT
DTC.CD Biotechnology & Medical Research

Dtc.Cd

$0,50
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
280,5 %
Net margin
Debt / equity
-1,20
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

DTC.CD operates in the healthcare diagnostics industry, providing diagnostic services and related healthcare solutions.

Business. DTC.CD operates in the healthcare diagnostics industry, providing diagnostic services and related healthcare solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
280,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning DTC.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to DTC.CD. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    DTC.CD operates in the healthcare diagnostics industry, providing diagnostic services and related healthcare solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    DTC.CD's capital structure is highly leveraged, with total liabilities of CAD 29.1 million and total equity of CAD -12.6 million, resulting in a debt-to-equity ratio of -1.2. The company's liquidity position is weak, as indicated by a current ratio of 0.5, suggesting that it may struggle to meet short-term obligations. Operating cash flow is negative at CAD -3.4 million, and free cash flow is also negative at CAD -3.45 million, indicating a lack of cash generation.

    Profitability metrics show significant underperformance. Return on equity is 2.80, which is low for a company in the healthcare diagnostics industry, and return on assets is -2.13, indicating that the company is not generating returns from its asset base. These figures are below the typical performance of industry peers, suggesting operational inefficiencies or market challenges.

    Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration is likely to be a concern given the negative net income and operating income. The lack of detailed segment reporting limits the ability to assess the performance of individual business lines or geographic regions.

    Growth trajectory is not evident from the data provided. The company reported a net loss of CAD 3.52 million and an operating loss of CAD 3.19 million, indicating a lack of growth and potential operational challenges. Without a clear path to profitability or revenue expansion, the company's future growth prospects are uncertain.

    Risk factors include liquidity constraints and the potential for dilution. The company has a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. Dilution risk is currently low, but the company's negative equity position and high debt levels could necessitate future equity issuance, which would dilute existing shareholders.

    Recent events and filings have not been provided in the dataset, so no specific recent developments can be cited. However, the company's financial position suggests that it may be under pressure to secure additional financing or restructure its debt.

    Key takeaways
    • DTC.CD has a weak liquidity position with a current ratio of 0.5 and negative operating and free cash flows.
    • The company's profitability is poor, with a return on equity of 2.80 and a return on assets of -2.13.
    • The company's capital structure is highly leveraged, with a debt-to-equity ratio of -1.2.
    • Growth prospects are uncertain due to the lack of revenue expansion and ongoing losses.
    • The company faces liquidity and potential dilution risks due to its negative equity and high debt levels.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,50
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$1.3M
    Net cash
    -$1.5M
    Current ratio
    0.5
    Debt / equity
    -1.2
    ROA
    -2.1%
    ROE
    2.8%
    Cash conversion
    97.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE280,5 %Best in class
    D/E-1,20Best in class
    Cash Conv0,97Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • DTC.CD Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Sebastien PlouffePresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    DTC.CDCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage